Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010

August 26, 2010 By Bio-Medicine.Org

RANCHO CORDOVA, Calif., Aug. 26 /PRNewswire-FirstCall/ —
ThermoGenesis Corp. (Nasdaq:
KOOL
), a leading supplier of innovative products and services
that process and store adult stem cells, said it has filed a
Certificate of Amendment to its Amended and Restated Certification
of Incorporation to effect its previously announced one-for-four
reverse stock split of its common stock.

The split-adjusted shares of the Company’s common stock will
begin trading on the NASDAQ tomorrow. The Company’s shares will
continue to trade under the symbol “KOOL,” with a “D” added for 20
trading days to signify the reverse stock split has occurred. A new
CUSIP number has been assigned to the Company’s common stock as a
result of the reverse stock split.

The one-for-four reverse stock split will convert all shares of
the Company’s common stock issued and outstanding, plus all
outstanding stock options, restricted stock and the number of
shares of common stock available for issuance under the Company’s
approved stock plans.

The reverse split was approved by the Company’s stockholders at
a special meeting and authorized by its Board of Directors on
August 9, 2010. It will reduce the Company’s outstanding common
stock from approximately 56.1 million shares, as of its most recent
quarterly report on Form 10-Q, to approximately 14.0 million
shares.

“We appreciate the support of our stockholders in approving this
authorization,” said J. Melville Engle, Chief Executive officer of
ThermoGenesis. “We ended fiscal 2010 in strong fashion and believe
the programs we have in place will result in a successful fiscal
2011 and lead to enhanced long term stockholder value as we
continue our focus on the development of enabling technologies for
the stem cell regenerative medicine market,” he added.

The Company said a reverse split may enable it to meet the
continued listing rules of the

‘/>”/>

SOURCE

Related Articles Read More >

TE Connectivity opens global medical device prototyping center in Ireland
Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech